Sandip I. Patel - Nov 14, 2024 Form 3 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Wendy F. DiCicco, as Attorney-in-Fact
Stock symbol
AKTX
Transactions as of
Nov 14, 2024
Transactions value $
$0
Form type
3
Date filed
11/22/2024, 04:30 PM
Previous filing
Feb 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AKTX Ordinary Shares, par value $0.0001 per share 904M Nov 14, 2024 Direct F1
holding AKTX Ordinary Shares, par value $0.0001 per share 12.5M Nov 14, 2024 By TT Insurance Investment LLC F1, F2
holding AKTX Ordinary Shares, par value $0.0001 per share 27.8M Nov 14, 2024 By Innovative Lifesci Investments LLC F1, F2
holding AKTX Ordinary Shares, par value $0.0001 per share 39.8M Nov 14, 2024 By Quest Bio LLC F1, F2
holding AKTX Ordinary Shares, par value $0.0001 per share 40.4M Nov 14, 2024 By Davis Island Ventures LLC F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AKTX Stock Option (Right to Buy) Nov 14, 2024 Ordinary Shares, par value $0.0001 per share 235M $0.00 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.
F2 These Ordinary Shares are held by LLCs of which the Reporting Person is the managing member. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
F3 Subject to the Reporting Person's continued service with the Issuer and there being an effective Form S-8 Registration Statement (a "Form S-8") on file with the SEC covering the issuance of the Ordinary Shares underlying such option, this option shall vest with respect to one third of the underlying shares on each of (i) the effective date of the Form S-8, (ii) December 31, 2024 and (iii) December 31, 2025.

Remarks:

Exhibit 24 - Power of Attorney